Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

Completed · Phase 2 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.

Key facts

Study ID

NCT00170768

Run by

Novartis

People needed

150

Starts

2005-02-01

Expected to finish

2005-05-01

Last updated by the study team

2008-01-23

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females aged 60 and over
• United States English as a primary language
• Given written informed consent by signing and dating an informed consent form prior to study entry

You may not qualify if…

• Current diseases in which the use of anti-cholinergic drugs is contraindicated, including the use of drugs with anti-cholinergic effects
• Volunteers with history of urinary retention or current bladder outlet obstruction, as determined by the investigator
• Other protocol defined inclusion/exclusion criteria may apply.
• Current use of drugs known to effect memory and cognition Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Washington Neuropsychological Institute LLC Georgetown — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.